

In another embodiment of the invention the labeled oligonucleotide sequence is directed against at least a target sequence in the glutathione-S-transferase (pi) gene. preferable target sequences of the glutathione-S-transferase (pi) gene would be as follows:

5' CTC CAG CGA CGG CCT CGC GGC CTC CGA GCC TTA TAA G 3' (SEQ ID NO: 4)  
 5' GGG GAC GCG GGC CGC GCG TAC TCA CTG GTG GCG A 3' (SEQ ID NO: 5)-

2. On page 16, please replace Table 1 with the following Table:

Molecular Beacon A	5'-(6FAM) <u>CGA GGC GGG CTG GAC GCG TCG GAG GCC TCG</u> (DABCYL)-3' (SEQ ID NO: 6)
Molecular Beacon B	5'-(6FAM) <u>CGA GGG GGC TGG ACG CGT CGG AGC CTC G</u> (DABCYL)-3' (SEQ ID NO: 7)
Complementary strand A	5'-CTC CGA CGC GTC CAG CCC G-3' (SEQ ID NO: 8)
Complementary strand B	5'-CTC CGA CGC GTC CAG CCC-3' (SEQ ID NO: 9)
5M	5'-GC <sub>m</sub> G GC <sub>m</sub> G ACT CC <sub>m</sub> G AC <sub>m</sub> G C <sub>m</sub> GT CCA GCC C <sub>m</sub> GC <sub>m</sub> GCT CC-3' (SEQ ID NO: 10)
Non-5M	5'- GCG GCG ACT CCG ACG CGT CCA GCC CGC GCT CC-3' (SEQ ID NO: 1)

C<sub>m</sub> = 5 methylated cytosines

5M = preferred Myf-3 target sequence, 5M methylated, Non-5M unmethylated (see page 12, line 8)

The stem sequences are underlined

3. On page 21, please replace the section titled "Methylated Oligonucleotides" with the following section:

### Methylated Oligonucleotides

5-5M 5'-GCG GCG ACT <sup>M M M</sup>CCG ACG CGT CCA GCC <sup>M M</sup>CGC GCT CC-3' (SEQ ID NO 11)  
 4-5M 5'-GCG GCG ACT <sup>M M</sup>CCG ACG CGT CCA GCC <sup>M M</sup>CGC GCT CC-3' (SEQ ID NO 12)  
 3-5M 5'-GCG GCG ACT <sup>M</sup>CCG ACG <sup>M M</sup>CGT CCA GCC <sup>M M</sup>CGC GCT CC-3' (SEQ ID NO 13)  
 2-5M 5'-GCG GCG ACT CCG ACG CGT CCA GCC <sup>M M</sup>CGC GCT CC-3' (SEQ ID NO 14)

M

1-5M 5'-GCG GCG ACT CCG ACG CGT CCA GCC CGC GCT CC-3' (SEQ  
ID NO 15)

M = methylated cytosine residues

NB. Reaction profiles shown in Fig.2

Modifications and variations such as would be apparent to the skilled addressee are considered to fall within the scope of the present invention.


#### REMARKS

A separate sheet is attached which shows the changes made to the original paragraphs and sections amended herein.

Applicants submit that submitted herewith is an original paper copy and an initial computer readable copy of the Sequence Listing as required by the Notice to File Missing Parts.

In accordance with 37 C.F.R. §1.821 (f)(g) Applicants hereby state that the paper copy and the computer readable form of the Sequence Listing submitted herewith in the above-identified patent application are supported in the application and contain no new matter. Applicants hereby further state that the information recorded in computer readable form is identical to the written sequence listing.

Date: December 3, 2001



Name: Paula Campbell Evans  
Registration No.: 32,503  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199  
Tel: 617-239-0100